Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1373386 | Bioorganic & Medicinal Chemistry Letters | 2010 | 6 Pages |
Abstract
We disclose here a series of P4-benzoxaborole-substituted macrocyclic HCV protease inhibitors. These inhibitors are potent against HCV NS3 protease, their anti-HCV replicon potencies are largely impacted by substitutions on benzoxaborole ring system and P2∗ groups. P2∗ 2-thiazole-isoquinoline provides best replicon potency. The in vitro SAR studies and in vivo PK evaluations of selected compounds are described herein.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Charles Z. Ding, Yong-Kang Zhang, Xianfeng Li, Yang Liu, Suoming Zhang, Yasheen Zhou, Jacob J. Plattner, Stephen J. Baker, Liang Liu, Maosheng Duan, Richard L. Jarvest, Jingjing Ji, Wieslaw M. Kazmierski, Matthew D. Tallant, Lois L. Wright,